Tisdag 26 November | 08:43:44 Europe / Stockholm
Svenska | English
Investor Relations
Public Relations

BICO Group

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-05-08 - Årsstämma
2025-04-29 07:00 Kvartalsrapport 2025-Q1
2025-02-19 07:00 Bokslutskommuniké 2024
2024-11-26 07:00 Kvartalsrapport 2024-Q3
2024-08-20 - Kvartalsrapport 2024-Q2
2024-05-21 - X-dag ordinarie utdelning BICO 0.00 SEK
2024-05-20 - Årsstämma
2024-05-07 - Kvartalsrapport 2024-Q1
2024-02-20 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-22 - Kvartalsrapport 2023-Q2
2023-05-10 - X-dag ordinarie utdelning BICO 0.00 SEK
2023-05-09 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-22 - Bokslutskommuniké 2022
2022-12-14 - Extra Bolagsstämma 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-24 - Kvartalsrapport 2022-Q2
2022-05-18 - Kvartalsrapport 2022-Q1
2022-04-27 - X-dag ordinarie utdelning BICO 0.00 SEK
2022-04-26 - Årsstämma
2022-02-23 - Bokslutskommuniké 2021
2021-11-17 - Extra Bolagsstämma 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-12 - Kvartalsrapport 2021-Q1
2021-04-27 - X-dag ordinarie utdelning BICO 0.00 SEK
2021-04-26 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-12-18 - X-dag ordinarie utdelning BICO 0.00 SEK
2020-12-17 - Extra Bolagsstämma 2020
2020-10-22 - Kvartalsrapport 2020-Q3
2020-04-09 - Kvartalsrapport 2020-Q2
2020-01-20 - Kvartalsrapport 2020-Q1
2020-01-10 - Split BICO 1:4
2019-12-19 - X-dag ordinarie utdelning BICO 0.00 SEK
2019-12-18 - Årsstämma
2019-10-24 - Bokslutskommuniké 2019
2019-08-26 - Extra Bolagsstämma 2019
2019-07-11 - Kvartalsrapport 2019-Q3
2019-04-10 - Kvartalsrapport 2019-Q2
2018-12-14 - X-dag ordinarie utdelning BICO 0.00 SEK
2018-12-13 - Årsstämma
2018-10-24 - Bokslutskommuniké 2018
2018-07-11 - Kvartalsrapport 2018-Q3
2018-04-11 - Kvartalsrapport 2018-Q2
2018-01-17 - Kvartalsrapport 2018-Q1
2017-12-15 - X-dag ordinarie utdelning BICO 0.00 SEK

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
BICO Group är verksamma inom medicinteknik. Bolaget är specialiserade inom biokonvergens och tillhandahåller teknik, produkter och tjänster för biologi. Med fokus på applikationsområdena bioprintning, multiomics, cellinjeutveckling och diagnostik utvecklar och marknadsför bolaget teknik som gör det möjligt för forskare att odla celler i 3D-miljöer, genomföra läkemedelsscreening och skriva ut mänskliga vävnader och organ för medicinsk, läkemedels- och kosmetisk industri.
Publication of BICO Group Interim report January-June 2024
2024-08-20 07:00:00

BICO Group AB 559050–5052 (NASDAQ STOCKHOLM: BICO).

April-June 2024 (compared with April-June 2023)

  • Net sales amounted to SEK 534.0m (537.0) which corresponds to a decrease of -0.6% compared to the corresponding quarter previous year
  • Organic sales growth for the quarter amounted to -1.8% (1.2%). From Q1 2024, BICO reports all organic growth figures in constant currency
  • The gross margin amounted to 51.5% (45.8%). From Q1 2024, BICO has changed to functional reporting and comparable numbers has been adjusted
  • Adjusted EBITDA amounted to SEK 45.7m (10.9) corresponding to a margin of 8.6% (2.0%)
  • EBITDA amounted to SEK 35.5m (160.1) corresponding to a margin of 6.6% (29.8%)
  • Net profit/loss for the quarter from continuing operations amounted to SEK -78.7m (-228.9) corresponding to earnings per share from continuing operations before and after dilution of SEK -1.10 (-3.24)
  • Cash flow from operating activities amounted to SEK -50.9m (-47.7)

January-June 2024 (compared with January-June 2023)

  • Net sales amounted to SEK 1,044.3m (1,025.7) which corresponds to an increase of 1.8% compared to the corresponding period previous year
  • Organic sales growth for the period amounted to 1.3% (0.1%). From Q1 2024, BICO reports all organic growth figures in constant currency
  • The gross margin amounted to 48.4% (48.5%). From Q1 2024, BICO has changed to functional reporting and comparable numbers has been adjusted
  • Adjusted EBITDA amounted to SEK 36.7m (37.0) corresponding to a margin of 3.5% (3.6%)
  • EBITDA amounted to SEK 16.5m (175.8) corresponding to a margin of 1.6% (17.1%)
  • Net profit/loss for the period from continuing operations amounted to SEK -107.9m (-305.4) corresponding to earnings per share from continuing operations before and after dilution of SEK -1.50 (-4.32)
  • Cash flow from operating activities amounted to SEK -68.2m (12.7)

Q2 takeaways

  • Stable sales levels, in line with peers, despite volatile market environment
  • All business areas EBITDA positive during the quarter
  • Catharina Nordlund assumed office as Chief HR Officer and Anders Fogelberg was appointed and assumed office as Chief Commercial Officer
  • Continuous work with strategic priorities to pave way for the updated strategy which will be presented during the Capital Markets Day on September 17, 2024

Significant events after Q2

  • Andréas Joersjö appointed General Counsel and will assume office by mid-October 2024 the latest

Presentation for media and investors
A telephone conference, with the opportunity to ask questions, will be held later today, on August 20, 2024, at 10:00am CEST, at which President & CEO Maria Forss and CFO Jacob Thordenberg will present the interim report.

The presentation will be available on BICO’s website from 09:00am CEST.
https://bico.com/investors/

If you wish to participate via webcast, please use the link below:
https://ir.financialhearings.com/bico-q2-report-2024/register

If you wish to participate via teleconference, please register on the link below:
After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://conference.financialhearings.com/teleconference/?id=5002813

For further information, please contact:
Maria Forss, President & CEO, BICO Group AB
Phone: EA Isabella Lundin +46 73 515 99 64
E-mail: mf@bico.com

Jacob Thordenberg, Chief Financial Officer, BICO Group AB
Phone: +46 73 534 88 84
E-mail: jt@bico.com

This information is information that BICO Group is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-20 07:00 CEST.

BICO Investor Relations
Phone: +46 735 46 57 77
E-mail: ir@bico.com

About BICO
BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 46,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 12,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction of the world’s organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

Attachments
BICO Group AB Q2 2024 EN

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden